GR3026332T3 - Improved oral dosing formulations of dideoxy purine nucleosides - Google Patents

Improved oral dosing formulations of dideoxy purine nucleosides

Info

Publication number
GR3026332T3
GR3026332T3 GR970402511T GR970402511T GR3026332T3 GR 3026332 T3 GR3026332 T3 GR 3026332T3 GR 970402511 T GR970402511 T GR 970402511T GR 970402511 T GR970402511 T GR 970402511T GR 3026332 T3 GR3026332 T3 GR 3026332T3
Authority
GR
Greece
Prior art keywords
improved oral
reduced mass
oral dosing
dideoxy purine
purine nucleosides
Prior art date
Application number
GR970402511T
Other languages
Greek (el)
English (en)
Inventor
Ismat Ullah
Shreeram Narahari Agharkar
Gary James Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3026332(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of GR3026332T3 publication Critical patent/GR3026332T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10Carbonates; Bicarbonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12Magnesium silicate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
GR970402511T 1991-07-22 1998-03-12 Improved oral dosing formulations of dideoxy purine nucleosides GR3026332T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73354791A 1991-07-22 1991-07-22
US88220492A 1992-05-13 1992-05-13

Publications (1)

Publication Number Publication Date
GR3026332T3 true GR3026332T3 (en) 1998-06-30

Family

ID=27112590

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970402511T GR3026332T3 (en) 1991-07-22 1998-03-12 Improved oral dosing formulations of dideoxy purine nucleosides

Country Status (23)

Country Link
US (1) US5880106A (enExample)
EP (1) EP0524579B1 (enExample)
JP (1) JP3038456B2 (enExample)
KR (1) KR960011772B1 (enExample)
CN (1) CN1042299C (enExample)
AT (1) ATE163855T1 (enExample)
AU (1) AU657337B2 (enExample)
CA (1) CA2074215C (enExample)
DE (1) DE69224684T2 (enExample)
DK (1) DK0524579T3 (enExample)
ES (1) ES2113389T3 (enExample)
FI (1) FI105153B (enExample)
GR (1) GR3026332T3 (enExample)
HU (3) HU9202318D0 (enExample)
IE (1) IE922365A1 (enExample)
IL (1) IL102519A (enExample)
MX (1) MX9204256A (enExample)
NO (1) NO300198B1 (enExample)
NZ (1) NZ243567A (enExample)
PL (1) PL295329A1 (enExample)
RU (1) RU2089193C1 (enExample)
TW (1) TW211521B (enExample)
ZA (1) ZA925484B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
CA2300892A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
EP1311240A1 (en) * 2000-08-14 2003-05-21 Fertin Pharma A/S Method for preparation of chewing gum with customer acceptable taste
US6887926B1 (en) 2001-11-16 2005-05-03 Oatey Co. Bonding compositions for chlorinated polymers and methods of using the same
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
RU2276992C2 (ru) * 2004-07-12 2006-05-27 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Фармацевтический состав, обладающий ноотропной активностью
US20080299227A1 (en) * 2007-05-30 2008-12-04 Sunhealth Therapies, Inc. Method for removal of HIV from the gastrointestinal tract and bile of HIV-infected subjects and for the prevention of drug failure and prevention of development of AIDS in HIV-infected subjects
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CN102949406B (zh) * 2011-08-31 2014-03-12 天津药物研究院 一种复方艾夫他滨药物组合物及其制备方法和用途
AR089857A1 (es) * 2012-02-02 2014-09-24 Glaxosmithkline Llc Comprimido antiacido para refrescar el aliento
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
CN104069126A (zh) * 2014-07-02 2014-10-01 浙江康乐药业股份有限公司 一种治疗胃酸过多的药物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260596A (en) * 1979-08-13 1981-04-07 Bristol-Myers Company Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 2′、3′―ジデオキシイノシン、2′,3′―ジデオキシグアノシンまたは2′,3′―ジデオキシアデノシンを含有する抗htlv―3/lav剤
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
CH674148A5 (enExample) * 1986-06-24 1990-05-15 Racz Istvan
WO1988002629A1 (en) * 1986-10-16 1988-04-21 American Health Products Corporation 2',3'-didesoxyadenosine composition
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds

Also Published As

Publication number Publication date
FI105153B (fi) 2000-06-30
CA2074215A1 (en) 1993-01-23
HUT61472A (en) 1993-01-28
ZA925484B (en) 1993-09-13
KR930001912A (ko) 1993-02-22
AU657337B2 (en) 1995-03-09
ES2113389T3 (es) 1998-05-01
NO922807L (no) 1993-01-25
IL102519A0 (en) 1993-01-14
RU2089193C1 (ru) 1997-09-10
FI923308A0 (fi) 1992-07-20
IL102519A (en) 1996-01-31
US5880106A (en) 1999-03-09
NZ243567A (en) 1995-04-27
DK0524579T3 (da) 1998-04-06
HU9202375D0 (en) 1992-10-28
CN1068739A (zh) 1993-02-10
FI923308L (fi) 1993-01-23
NO922807D0 (no) 1992-07-16
ATE163855T1 (de) 1998-03-15
PL295329A1 (en) 1993-04-05
KR960011772B1 (ko) 1996-08-30
HU9202318D0 (en) 1992-10-28
TW211521B (enExample) 1993-08-21
IE922365A1 (en) 1992-11-18
HU211285A9 (en) 1995-11-28
HU220612B1 (hu) 2002-03-28
MX9204256A (es) 1993-01-01
DE69224684T2 (de) 1998-11-12
JP3038456B2 (ja) 2000-05-08
CA2074215C (en) 2001-12-18
NO300198B1 (no) 1997-04-28
EP0524579B1 (en) 1998-03-11
DE69224684D1 (de) 1998-04-16
EP0524579A1 (en) 1993-01-27
AU2039692A (en) 1993-01-28
JPH05194234A (ja) 1993-08-03
CN1042299C (zh) 1999-03-03

Similar Documents

Publication Publication Date Title
AU657337B2 (en) Improved oral dosing formulations of dideoxy purine nucleosides
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
PT90466A (pt) Processo de preparacao de composicoes farmaceuticas compreendendo um excipiente extragranular, higroscopio insoluvel em agua e um ingrediente activo, em particular a cimetidina
ATE125155T1 (de) Niedrigdosierte getrocknete pharmazeutische präparate.
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
ATE139438T1 (de) Kaubare antacida
TH7600B (th) สูตรผสมซึ่งให้ทางปากที่ดีขึ้นของไดดีออกซีพิวรีนนิวคลีโอไซด์
TH13488A (th) สูตรผสมซึ่งให้ทางปากที่ดีขึ้นของไดดีออกซีพิวรีนนิวคลีโอไซด์
ITRM910038A1 (it) Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.